Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neuromuscular diseases

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases

- PMLiVE

Alzheimer’s Society raises concerns over undiagnosed young-onset dementia cases

The UK charity estimates that over 19,000 people in England are living without a diagnosis

- PMLiVE

AstraZeneca studies highlight burden of COVID-19 for immunocompromised

The risk of hospitalisation due to COVID-19 was 14 times greater for IC individuals

- PMLiVE

New Swedish study finds HSCT can slow progression of multiple sclerosis

More than 70% of participants in the study had no new progression after five years of treatment

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

Alzheimer’s Research UK launches ‘Change The Ending’ campaign

A survey revealed that 22% of 2,162 people were unaware of the impact dementia has on people’s everyday lives

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links